Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 1
- 17. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
Cited by
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
“…described cohorts of adult AML patients: (1) a training dataset of 285 patients with diverse cytogenetic and molecular abnormalities described by Valk et al. (2004), (2) a test dataset of 242 patients with normal karyotypes described by Metzeler et al. (2008), and (3) a validation dataset of…”
MethodInfluentialMutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D., Dunford-Shore, B. H., McGrath, S., Hickenbotham, M., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,422
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Stem cell gene expression programs influence clinical outcome in human leukemia
Eppert, K., Takenaka, K., Lechman, E. R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K. H., Poeppl, A., Ling, V., Beyene, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2415 · Cited by 1,041
“LSC and HSC signatures predict patient survival To test the clinical relevance of LSCs, we investigated the correlation between LSC-R and HSC-R gene signatures and clinical outcomes using three large clinically annotated gene expression data sets derived from unsorted AML cell”
Methodon behalf of the EuroFlow Consortium (EU-FP6, L.-C.-2.-0., van Dongen, J. J. M., Lhermitte, L., Böttcher, S., Almeida, J., van der Velden, V. H. J., Flores-Montero, J., Rawstron, A., Asnafi, V, Lécrevisse, Q., et al. (2012) · Leukemia · doi:10.1038/leu.2012.120 · Cited by 934
Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationDensely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis
Novershtern, N., Subramanian, A., Lawton, L. N., Mak, R. H., Haining, W. N., McConkey, M. E., Habib, N., Yosef, N., Chang, C. Y., Shay, T., et al. (2011) · Cell · doi:10.1016/j.cell.2011.01.004 · Cited by 942
“Impaired or blocked hematopoietic differentiation is a defining characteristic of leukemia, and the gene expression profiles of leukemias cluster strongly into subgroups that correspond to specific molecular subgroups (Bullinger et al., 2004; Tamayo et al., 2007; Valk et al., 2004).”
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P. J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.020 · Cited by 833
“0 GeneChips. mRNA isolation, labeling, hybridization, and quality control were carried out as described previously (Valk et al., 2004 ).”
BackgroundMethodInfluentialSelf-citationIntrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology
Gravendeel, L. A. M., Kouwenhoven, M. C. M., Gevaert, O., de Rooi, J. J., Stubbs, A. P., Duijm, J. E., Daemen, A., Bleeker, F. E., Bralten, L. B. C., Kloosterhof, N. K., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2307 · Cited by 678
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronnie, G. T., Béné, M.-C., De Vos, J., Hernández, J. M., Hofmann, W.-K., Mills, K. I., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4732 · Cited by 654
“C13: AML with t(11q23)/MLL C12: AML with inv(16)/t(16;16) C11: AML with t(15;17) C10: AML with t(8;21) C9: c-ALL/Pre-B-ALL without t(9;22) C8: ALL with hyperdiploid karyotype C7: ALL with t(1;19) C6: ALL with t(12;21) C5: T-ALL C4: c-ALL/Pre-B-ALL with t(9;22) C3: Pro-B-ALL with t(11q23)/MLL C2: Mature B-ALL with t(8;…”
MethodXiao, Y., Cong, M., Li, J., He, D., Wu, Q., Tian, P., Wang, Y., Yang, S., Liang, C., Liang, Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.012 · Cited by 649
Khwaja, A., Bjorkholm, M., Gale, R. E., Levine, R. L., Jordan, C. T., Ehninger, G., Bloomfield, C. D., Estey, E., Burnett, A., Cornelissen, J. J., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.10 · Cited by 592
Verhaak, R. G. W., Goudswaard, C. S., van Putten, W., Bijl, M. A., Sanders, M. A., Hugens, W., Uitterlinden, A. G., Erpelinck, C. A. J., Delwel, R., Löwenberg, B., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2168 · Cited by 618
Self-citationWouters, B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L. J., Valk, P. J. M., & Delwel, R. (2009) · Blood · doi:10.1182/blood-2008-09-179895 · Cited by 566
Self-citationFalini, B., Nicoletti, I., Martelli, M. F., & Mecucci, C. (2007) · Blood · doi:10.1182/blood-2006-07-012252 · Cited by 565
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marcucci, G., Haferlach, T., & Döhner, H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2554 · Cited by 570
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 541
Mrózek, K., Marcucci, G., Paschka, P., Whitman, S. P., & Bloomfield, C. D. (2007) · Blood · doi:10.1182/blood-2006-06-001149 · Cited by 552
Roepman, P., Wessels, L. F. A., Kettelarij, N., Kemmeren, P., Miles, A. J., Lijnzaad, P., Tilanus, M. G. J., Koole, R., Hordijk, G.-J., van der Vliet, P. C., et al. (2005) · Nature Genetics · doi:10.1038/ng1502 · Cited by 517
A tumor suppressor and oncogene: the WT1 story
Yang, L., Han, Y., Saurez Saiz, F., & Minden, M. D. (2007) · Leukemia · doi:10.1038/sj.leu.2404624 · Cited by 471
Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000349 · Cited by 458
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations
Li, Z., Lu, J., Sun, M., Mi, S., Zhang, H., Luo, R. T., Chen, P., Wang, Y., Yan, M., Qian, Z., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808266105 · Cited by 457
Gaidzik, V. I., Bullinger, L., Schlenk, R. F., Zimmermann, A. S., Röck, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7926 · Cited by 456
Terwijn, M., van Putten, W. L. J., Kelder, A., van der Velden, V. H. J., Brooimans, R. A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G. E., Valk, P. J. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9628 · Cited by 442
“Currently, the most important prognostic factors at diagnosis encompass cytogenetics and molecular abnormalities.(1-4) Although of utmost importance in risk stratification, treatment outcome for specifically defined risk groups is still highly variable, especially in intermediate-risk AML.”
BackgroundSelf-citationMetzeler, K. H., Hummel, M., Bloomfield, C. D., Spiekermann, K., Braess, J., Sauerland, M.-C., Heinecke, A., Radmacher, M., Marcucci, G., Whitman, S. P., et al. (2008) · Blood · doi:10.1182/blood-2008-02-134411 · Cited by 363
“Median platelet count, 109/L (range) 56 (6-471) 64 (9-239) .”
MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia
Marcucci, G., Radmacher, M. D., Maharry, K., Mrózek, K., Ruppert, A. S., Paschka, P., Vukosavljevic, T., Whitman, S. P., Baldus, C. D., Langer, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074256 · Cited by 441
Gene expression profiling of pediatric acute myelogenous leukemia
Ross, M. E., Mahfouz, R., Onciu, M., Liu, H.-C., Zhou, X., Song, G., Shurtleff, S. A., Pounds, S., Cheng, C., Ma, J., et al. (2004) · Blood · doi:10.1182/blood-2004-03-1154 · Cited by 448
Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044974 · Cited by 416
“at least 60% to 80%, a level consistent with prior genomic studies of cancer biology and outcome.(14,42,43) Fluorescence cell sorting analysis (FACS) of pre- and post-enrichment samples demonstrated that enrichment could yield samples of 80% to 90% tumor cells (Figure 1A).”
ResultGentles, A. J. (2010) · JAMA · doi:10.1001/jama.2010.1862 · Cited by 395
“Follow-up, median (IQR), mo 9 (3-27) 17 (7-73) 25 (10-55) 10 (2-22)”
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
Jongen-Lavrencic, M., Sun, S. M., Dijkstra, M. K., Valk, P. J. M., & Löwenberg, B. (2008) · Blood · doi:10.1182/blood-2008-01-133355 · Cited by 403
Self-citationDrukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0188 · Cited by 402
Performance of feature-selection methods in the classification of high-dimension data
Hua, J., Tembe, W. D., & Dougherty, E. R. (2009) · Pattern Recognition · doi:10.1016/j.patcog.2008.08.001 · Cited by 395
Taskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M. A., Erpelinck, C. A. J., Wouters, B. J., van der Poel-van de Luytgaarde, S. C., Damm, F., Krauter, J., Ganser, A., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307280 · Cited by 384
“Median (range) 65 (5-746) 62 (10-361) 38 (4-265)”
Self-citationMarcucci, G., Mrózek, K., Ruppert, A. S., Maharry, K., Kolitz, J. E., Moore, J. O., Mayer, R. J., Pettenati, M. J., Powell, B. L., Edwards, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.15.610 · Cited by 381
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia
Ntziachristos, P., Tsirigos, A., Welstead, G. G., Trimarchi, T., Bakogianni, S., Xu, L., Loizou, E., Holmfeldt, L., Strikoudis, A., King, B., et al. (2014) · Nature · doi:10.1038/nature13605 · Cited by 365
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Alcalay, M., Tiacci, E., Bergomas, R., Bigerna, B., Venturini, E., Minardi, S. P., Meani, N., Diverio, D., Bernard, L., Tizzoni, L., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0560 · Cited by 357
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling
Verhaak, R. G. W., Wouters, B. J., Erpelinck, C. A. J., Abbas, S., Beverloo, H. B., Lugthart, S., Lowenberg, B., Delwel, R., & Valk, P. J. M. (2009) · Haematologica · doi:10.3324/haematol.13299 · Cited by 359
“White blood cell count (×10(9)/L) 30 (0-278) 29 (1-349)”
BackgroundResultInfluentialSelf-citationSriskanthadevan, S., Jeyaraju, D. V., Chung, T. E., Prabha, S., Xu, W., Skrtic, M., Jhas, B., Hurren, R., Gronda, M., Wang, X., et al. (2015) · Blood · doi:10.1182/blood-2014-08-594408 · Cited by 329
“In addition, we analyzed the expression of the earlier mitochondrial biogenesis factors using a public dataset of 283 primary AML samples.(13) Similar to the previously mentioned findings, a subset of AML patients had increased expression of mitochondrial biogenesis factors (supplemental Figure 1).”
ResultFeature selection via dependence maximization
Song, L., Smola, A. J., Gretton, A., Bedő, J., & Borgwardt, K. M. (2012) · Journal of Machine Learning Research · doi:10.5555/2188385.2343691 · Cited by 495
Hollink, I. H. I. M., van den Heuvel-Eibrink, M. M., Arentsen-Peters, S. T. C. J. M., Pratcorona, M., Abbas, S., Kuipers, J. E., van Galen, J. F., Beverloo, H. B., Sonneveld, E., Kaspers, G.-J. J. L., et al. (2011) · Blood · doi:10.1182/blood-2011-04-346643 · Cited by 334
Self-citationMicroenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia
Wei, J., Wunderlich, M., Fox, C., Alvarez, S., Cigudosa, J. C., Wilhelm, J. S., Zheng, Y., Cancelas, J. A., Gu, Y., Jansen, M., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.020 · Cited by 284
“two large AML microarray studies were used for comparison (Ross et al., 2004; Valk et al., 2004).”
BackgroundMethodInfluentialErion, G., Janizek, J. D., Sturmfels, P., Lundberg, S. M., & Lee, S.-I. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00343-w · Cited by 300
“Furthermore, the pathways our model uses more closely match biological expert knowledge, that is, they included prognostically useful AML gene expression profiles as well as important AML-related transcription factors (Supplementary Section I) 34,35 .”
MethodDufour, A., Schneider, F., Metzeler, K. H., Hoster, E., Schneider, S., Zellmeier, E., Benthaus, T., Sauerland, M.-C., Berdel, W. E., Büchner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6010 · Cited by 293
Akalin, A., Garrett-Bakelman, F. E., Kormaksson, M., Busuttil, J., Zhang, L., Khrebtukova, I., Milne, T. A., Huang, Y., Biswas, D., Hess, J. L., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002781 · Cited by 296
“MLLr AMLs we examined gene expression microarray profiles from the same AML cases [10,40].”
MethodSelf-citationEvi-1 Is a Critical Regulator for Hematopoietic Stem Cells and Transformed Leukemic Cells
Goyama, S., Yamamoto, G., Shimabe, M., Sato, T., Ichikawa, M., Ogawa, S., Chiba, S., & Kurokawa, M. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.06.002 · Cited by 287
Zhou, W., Yang, Y., Xia, J., Wang, H., Salama, M. E., Xiong, W., Xu, H., Shetty, S., Chen, T., Zeng, Z., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.001 · Cited by 288
Nutrigenomics: From Molecular Nutrition to Prevention of Disease
Afman, L., & Müller, M. (2006) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2006.01.001 · Cited by 285
Lugthart, S., van Drunen, E., van Norden, Y., van Hoven, A., Erpelinck, C. A. J., Valk, P. J. M., Beverloo, H. B., Löwenberg, B., & Delwel, R. (2008) · Blood · doi:10.1182/blood-2007-10-119230 · Cited by 280
Self-citationDysregulated gene expression networks in human acute myelogenous leukemia stem cells
Majeti, R., Becker, M. W., Tian, Q., Lee, T.-L. M., Yan, X., Liu, R., Chiang, J.-H., Hood, L., Clarke, M. F., & Weissman, I. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900089106 · Cited by 281
“5 including several very large cohorts (16-18).”
Core circadian clock genes regulate leukemia stem cells in AML
Puram, R. V., Kowalczyk, M. S., de Boer, C. G., Schneider, R. K., Miller, P. G., McConkey, M., Tothova, Z., Tejero, H., Heckl, D., Järås, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.015 · Cited by 274
“…can be effectively examined in such an in vivo screen, we first identified candidate TFs on the basis of gene expression (Bullinger et al., 2004; Chen et al., 2008; Krivtsov et al., 2009; Metzeler et al., 2008; Novershtern et al., 2011; Somervaille et al., 2009; Valk et al., 2004; Wang et al., 2010).”
Functional proteomic profiling of AML predicts response and survival
Kornblau, S. M., Tibes, R., Qiu, Y. H., Chen, W., Kantarjian, H. M., Andreeff, M., Coombes, K. R., & Mills, G. B. (2009) · Blood · doi:10.1182/blood-2007-10-119438 · Cited by 263
“A similar clustering of -5 and -7 were observed with GEP.(12) Thus it appears that the different cytogenetic changes have similar effects on protein expression and activation within AML blasts.”
BackgroundNatural population dynamics and expansion of pathogenic clones of Staphylococcus aureus
Melles, D. C., Gorkink, R. F. J., Boelens, H. A. M., Snijders, S. V., Peeters, J. K., Moorhouse, M. J., van der Spek, P. J., van Leeuwen, W. B., Simons, G., Verbrugh, H. A., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200423083 · Cited by 255
Self-citationMyc Roles in Hematopoiesis and Leukemia
Delgado, M. D., & Leon, J. (2010) · Genes & Cancer · doi:10.1177/1947601910377495 · Cited by 255
Kim, K.-T., Baird, K., Ahn, J.-Y., Meltzer, P., Lilly, M., Levis, M., & Small, D. (2005) · Blood · doi:10.1182/blood-2004-05-2006 · Cited by 234
Tribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemia
Keeshan, K., He, Y., Wouters, B. J., Shestova, O., Xu, L., Sai, H., Rodriguez, C. G., Maillard, I., Tobias, J. W., Valk, P., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.012 · Cited by 238
“Correlation view of 285 AML patients (Valk et al., 2004).”
BackgroundInfluentialSelf-citationLi, L., Osdal, T., Ho, Y., Chun, S., McDonald, T., Agarwal, P., Lin, A., Chu, S., Qi, J., Li, L., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.08.001 · Cited by 234
“…two large AML gene expression data sets available through the Gene Expression Omnibus (GSE1159: FLT3-ITD AML [n = 73] versus FLT3WT AML [n = 178] [Valk et al., 2004] and GSE8043: FLT3-ITD AML [n = 120] versus FLT3-WT AML [n = 291] [Bullinger et al., (E and F) FLT3-ITD AML (n = 11), FLT3-WT AML…”
BackgroundChen, W.-L., Wang, Y.-Y., Zhao, A., Xia, L., Xie, G., Su, M., Zhao, L., Liu, J., Qu, C., Wei, R., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.006 · Cited by 227
“We analyzed the relevance of SLC2A5 expression to the survival of AML patients in five previously published gene expression datasets (Bullinger et al., 2004; Metzeler et al., 2008; Valk et al., 2004).”
Warnat, P., Eils, R., & Brors, B. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-265 · Cited by 228
“While differences between the first three groups are prominent and were detected in multiple studies [33,26,27], evidence about the homogeneity of the normal karyotype group and the associated genes is still lacking.”
InfluentialDistinctive Patterns of MicroRNA Expression Associated with Karyotype in Acute Myeloid Leukaemia
Dixon-McIver, A., East, P., Mein, C. A., Cazier, J.-B., Molloy, G., Chaplin, T., Andrew Lister, T., Young, B. D., & Debernardi, S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002141 · Cited by 225
“sets of genes with expression patterns highly correlated with each karyotypic class [4–8] and so providing a better understanding of the underlying disease biology.”
BackgroundPediatric AML: From Biology to Clinical Management
De Rooij, J., Zwaan, C., & Van den Heuvel-Eibrink, M. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4010127 · Cited by 208
“Gene expression profiling could predict the cytogenetic subtypes of AML with high accuracy, although its value for diagnostic purposes remains limited, since most aberrations can be identified with conventional karyotyping [92–95].”
BackgroundDNA-microarray analysis of brain cancer: molecular classification for therapy
Mischel, P. S., Cloughesy, T. F., & Nelson, S. F. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1518 · Cited by 219
The M2 macrophage marker CD206 : a novel prognostic indicator for acute myeloid leukemia
Xu, Z.-J., Gu, Y., Wang, C.-Z., Jin, Y., Wen, X.-M., Ma, J.-C., Tang, L.-J., Mao, Z.-W., Qian, J., & Lin, J. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1683347 · Cited by 208
Vadakekolathu, J., Minden, M. D., Hood, T., Church, S. E., Reeder, S., Altmann, H., Sullivan, A. H., Viboch, E. J., Patel, T., Ibrahimova, N., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz0463 · Cited by 216
“Patient series PMCC CHOP SAL # of patients 290 39 38 Age (0-39), n 76 39 11 Age (40-59), n 126 0 15 Age (>60), n 88 0 12 Median age (years, range) 52 (18-81) 10 (0.”
Self-citationDysregulation of the C/EBPα Differentiation Pathway in Human Cancer
Koschmieder, S., Halmos, B., Levantini, E., & Tenen, D. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9812 · Cited by 212
“Genome-wide gene expression analysis of blasts from AML patients using unsupervised clustering revealed that C/EBP mutant cases cluster together, suggesting that they share similar gene expression signatures.(49)C/EBP mutations (15% of all CN-AML cases) do not segregate with any other known mutations, such as NPM1, Fl…”
MethodMalignant Transformation Initiated by Mll-AF9: Gene Dosage and Critical Target Cells
Chen, W., Kumar, A. R., Hudson, W. A., Li, Q., Wu, B., Staggs, R. A., Lund, E. A., Sam, T. N., & Kersey, J. H. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.005 · Cited by 211
“High levels of expression of Evi1, have been reported in human myeloid leukemias with MLL-rearrangements (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2003; Valk et al., 2004).”
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias
Falini, B., Nicoletti, I., Bolli, N., Martelli, M. P., Liso, A., Gorello, P., Mandelli, F., Mecucci, C., & Martelli, M. F. (2007) · Haematologica · doi:10.3324/haematol.11007 · Cited by 211
Lin, L.-I., Chen, C.-Y., Lin, D.-T., Tsay, W., Tang, J.-L., Yeh, Y.-C., Shen, H.-L., Su, F.-H., Yao, M., Huang, S.-Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1816 · Cited by 214
Gfi1 and Gfi1b: key regulators of hematopoiesis
van der Meer, L. T., Jansen, J. H., & van der Reijden, B. A. (2010) · Leukemia · doi:10.1038/leu.2010.195 · Cited by 211
“60 and large variations of Gfi1 expression were detected in different acute myeloid leukemia subtypes”
BackgroundLi, Z., Herold, T., He, C., Valk, P. J. M., Chen, P., Jurinovic, V., Mansmann, U., Radmacher, M. D., Maharry, K. S., Sun, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3184 · Cited by 206
Self-citationGlobal approach to the diagnosis of leukemia using gene expression profiling
Haferlach, T., Kohlmann, A., Schnittger, S., Dugas, M., Hiddemann, W., Kern, W., & Schoch, C. (2005) · Blood · doi:10.1182/blood-2004-12-4938 · Cited by 209
Greiner, J., Schmitt, M., Li, L., Giannopoulos, K., Bosch, K., Schmitt, A., Dohner, K., Schlenk, R. F., Pollack, J. R., Dohner, H., et al. (2006) · Blood · doi:10.1182/blood-2006-01-023127 · Cited by 205
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML
Krivtsov, A. V., Figueroa, M. E., Sinha, A. U., Stubbs, M. C., Feng, Z., Valk, P. J. M., Delwel, R., Döhner, K., Bullinger, L., Kung, A. L., et al. (2013) · Leukemia · doi:10.1038/leu.2012.363 · Cited by 203
Self-citationBarreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
HMGA2 as a Critical Regulator in Cancer Development
Mansoori, B., Mohammadi, A., Ditzel, H. J., Duijf, P. H. G., Khaze, V., Gjerstorff, M. F., & Baradaran, B. (2021) · Genes · doi:10.3390/genes12020269 · Cited by 201
Wouters, B. J., Jordà, M. A., Keeshan, K., Louwers, I., Erpelinck-Verschueren, C. A. J., Tielemans, D., Langerak, A. W., He, Y., Yashiro-Ohtani, Y., Zhang, P., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073486 · Cited by 199
“In a GEP study of 285 cases of de novo AML, we found that specific expression profiles are associated with other recurrent genetic aberrations such as mutations in NPM1, alterations involving MLL, and with overexpression of the proto-oncogene EVI1 as well.(4,6) Some AMLs lacking these particular abnormalities were fou…”
BackgroundMethodInfluentialSelf-citationMeta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes
Grützmann, R., Boriss, H., Ammerpohl, O., Lüttges, J., Kalthoff, H., Schackert, H. K., Klöppel, G., Saeger, H. D., & Pilarsky, C. (2005) · Oncogene · doi:10.1038/sj.onc.1208696 · Cited by 201
“Identification of signature genes by gene expression profiling for diagnostic and other purposes has been applied to numerous cancers (Liotta and Petricoin, 2000; Valk et al., 2004).”
BackgroundRiether, C., Schürch, C. M., Bührer, E. D., Hinterbrandner, M., Huguenin, A.-L., Hoepner, S., Zlobec, I., Pabst, T., Radpour, R., & Ochsenbein, A. F. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20152008 · Cited by 191
Wilson, C. S. (2006) · Blood · doi:10.1182/blood-2004-12-4633 · Cited by 190
“Median platelet count, 109/L (range) 53 (2-1052)”
InfluentialCEBPA point mutations in hematological malignancies
Leroy, H., Roumier, C., Huyghe, P., Biggio, V, Fenaux, P., & Preudhomme, C. (2005) · Leukemia · doi:10.1038/sj.leu.2403614 · Cited by 190
Identification of genes with abnormal expression changes in acute myeloid leukemia
Stirewalt, D. L., Meshinchi, S., Kopecky, K. J., Fan, W., Pogosova‐Agadjanyan, E. L., Engel, J. H., Cronk, M. R., Dorcy, K. S., McQuary, A. R., Hockenbery, D., et al. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20500 · Cited by 191
“Microarray data was obtained from AML patients enrolled on protocols from the Dutch-Belgian HematologyOncology Cooperative group (Supplement 1) (Valk et al., 2004).”
BackgroundMethodInfluentialEssential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells
Steidl, U., Rosenbauer, F., Verhaak, R. G. W., Gu, X., Ebralidze, A., Otu, H. H., Klippel, S., Steidl, C., Bruns, I., Costa, D. B., et al. (2006) · Nature Genetics · doi:10.1038/ng1898 · Cited by 184
“Although recent studies have shown that gene expression profiling of leukemic blast cells in human AML is of diagnostic importanc”
ResultSelf-citationAutocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
Kentsis, A., Reed, C., Rice, K. L., Sanda, T., Rodig, S. J., Tholouli, E., Christie, A., Valk, P. J. M., Delwel, R., Ngo, V., et al. (2012) · Nature Medicine · doi:10.1038/nm.2819 · Cited by 179
Self-citationIL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Schinke, C., Giricz, O., Li, W., Shastri, A., Gordon, S., Barreyro, L., Bhagat, T., Bhattacharyya, S., Ramachandra, N., Bartenstein, M., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621631 · Cited by 180
“It has been shown that leukemia-initiating cells can reside in different phenotypic stem and progenitor compartments at relatively low frequencies and are associated with transcription factor alterations that result inpathogenic transcriptional changes.(2-7,11-13,32,42-44) Thus, to uncover newer stem cell-directed tar…”
BackgroundThe potential of using blood circular RNA as liquid biopsy biomarker for human diseases
Wen, G., Zhou, T., & Gu, W. (2021) · Protein & Cell · doi:10.1007/s13238-020-00799-3 · Cited by 177
Gupta, V., Tallman, M. S., & Weisdorf, D. J. (2011) · Blood · doi:10.1182/blood-2010-10-265603 · Cited by 178
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis
Lam, K. (2012) · Frontiers in Bioscience · doi:10.2741/3977 · Cited by 167
“Another study looked at 285 samples from patients with various types of AML and were able to place t(8,21)-positive patients into a unique cluster based on their gene profiles alone (163).”
BackgroundJung, N., Dai, B., Gentles, A. J., Majeti, R., & Feinberg, A. P. (2015) · Nature Communications · doi:10.1038/ncomms9489 · Cited by 168
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia
Beekman, R., Valkhof, M. G., Sanders, M. A., van Strien, P. M. H., Haanstra, J. R., Broeders, L., Geertsma-Kleinekoort, W. M., Veerman, A. J. P., Valk, P. J. M., Verhaak, R. G., et al. (2012) · Blood · doi:10.1182/blood-2012-01-406116 · Cited by 177
Self-citationSynthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Esposito, M. T., Zhao, L., Fung, T. K., Rane, J. K., Wilson, A., Martin, N., Gil, J., Leung, A. Y., Ashworth, A., & Eric So, C. W. (2015) · Nature Medicine · doi:10.1038/nm.3993 · Cited by 167
Kittleson, M. M., Minhas, K. M., Irizarry, R. A., Ye, S. Q., Edness, G., Breton, E., Conte, J. V., Tomaselli, G., Garcia, J. G. N., & Hare, J. M. (2005) · Physiological Genomics · doi:10.1152/physiolgenomics.00255.2004 · Cited by 174
“We identified differentially expressed genes with SAM, which has been validated in a number of studies (6, 41, 49, 50) and may be more accurate than other commonly used methods for identifying differentially expressed genes, such as t-tests (43).”
Method
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.